Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery

dc.creatorWajnberg, Gabriel
dc.creatorPassetti, Fabio
dc.date2017-12-30T13:11:40Z
dc.date2017-12-30T13:11:40Z
dc.date2016
dc.date.accessioned2023-09-27T00:08:37Z
dc.date.available2023-09-27T00:08:37Z
dc.identifierWAJNBERG, Gabriel; PASSETTI, Fabio. Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery. Expert Opinion on Drug Discovery, v.11, n.3, p.257-268, 2016.
dc.identifier1746-0441
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/23832
dc.identifier10.1517/17460441.2016.1143813
dc.identifier1746-045X
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8897861
dc.descriptionA cancer cell is a mosaic of genomic and epigenomic alterations. Distinct cancer molecular signatures can be observed depending on tumor type or patient genetic background. One type of genomic alteration is the insertion and/or deletion (INDEL) of nucleotides in the DNA sequence, which may vary in length, and may change the encoded protein or modify protein domains. INDELs are associated to a large number of diseases and their detection is done based on low-throughput techniques. However, high-throughput sequencing has also started to be used for detection of novel disease-causing INDELs. This search may identify novel drug targets.
dc.description2030-01-01
dc.formatapplication/pdf
dc.languageeng
dc.publisherTaylor & Francis
dc.rightsrestricted access
dc.subjectCâncer
dc.subjectMedicamentos
dc.subjectMutação INDEL
dc.subjectSequência de Bases
dc.subjectCancer
dc.subjectDrug discovery
dc.subjectINDEL
dc.subjectDNA sequence
dc.titleUsing high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery
dc.typeArticle


Este ítem pertenece a la siguiente institución